Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Murray Kwon

Surgery Los Angeles, CA Medical Doctor

NPI 1841482981 CMS profile 356595

100 Ucla Medical Plz Ste 630, Los Angeles, CA 90024

Open in the dashboard

General payments

$26,650

235 records reported · program years 2019–2025

Research payments

$950

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Murray Kwon of Los Angeles, CA is reported in the CMS Open Payments database as having received $26,650 across 235 general payments and $950 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,374 46
2024 General $4,767 27
2023 General $3,641 29
2022 General $570 14
2021 General $4,986 42
2020 General $987 29
2020 Research $950 1
2019 General $5,324 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Murray Kwon
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Murray Kwon were reported at $6,374. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Murray Kwon Surgery median Middle half National median
2019 $5,324 $253 $82–$1,521 $163
2020 $987 $131 $40–$706 $114
2021 $4,986 $168 $50–$904 $132
2022 $570 $224 $76–$1,218 $149
2023 $3,641 $253 $82–$1,255 $160
2024 $4,767 $279 $90–$1,381 $164
2025 $6,374 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $20,250 197 payments
  2. Davol Inc. $3,382 4 payments
  3. Medtronic, Inc. $795 11 payments
  4. Abiomed $656 5 payments
  5. Ethicon US, LLC $605 1 payment
  6. Medtronic Vascular, Inc. $488 6 payments
  7. Bolton Medical Inc $159 1 payment
  8. Boston Scientific Corporation $141 2 payments
  9. Abbott Laboratories $71 3 payments
  10. Atricure, Inc. $45 2 payments
  11. Other $57 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,909 7 payments
  2. Food and Beverage $9,427 219 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 1 payment
  4. Travel and Lodging $1,864 7 payments
  5. Honoraria $450 1 payment
Products named General payments · program years 2019–2025
  1. SAPIEN 3 Ultra RESILIA $2,182 54 payments
  2. Edwards SAPIEN 3 Transcatheter Heart Valve $1,351 33 payments
  3. MITRIS RESILIA Mitral Valve $1,011 12 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $960 24 payments
  5. COREVALVE EVOLUT R $734 9 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $633 22 payments
  7. PROLENE Sutures $605 1 payment
  8. PROLENE Sutures $605 1 payment
  9. Impella $498 3 payments
  10. HeartWare HVAD $488 6 payments
  11. Other $1,580 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. US Endoscopy $950 1 payment

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$186,694

Medicare's payments for the services billed

Medicare patients

203

Average age 76

Services billed

523

84 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 60%
Chronic kidney disease 54%
Arthritis 52%
Diabetes 51%
Atrial fibrillation 47%
Cancer 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record